Tolerogenic nanoparticles induce type II collagen-specific regulatory T cells and ameliorate osteoarthritis.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 36427299.
- Also identified by DOI 10.1126/sciadv.abo5284 and PMC identifier 9699678.
- Licence recorded as CC BY-NC.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Local inflammation in the joint is considered to contribute to osteoarthritis (OA) progression. Here, we describe an immunomodulating nanoparticle for OA treatment. Intradermal injection of lipid nanoparticles (LNPs) loaded with type II collagen (Col II) and rapamycin (LNP-Col II-R) into OA mice effectively induced Col II-specific anti-inflammatory regulatory T cells, substantially increased anti-inflammatory cytokine expression, and reduced inflammatory immune cells and proinflammatory cytokine expression in the joints. Consequently, LNP-Col II-R injection inhibited chondrocyte apoptosis and cartilage matrix degradation and relieved pain, while injection of LNPs loaded with a control peptide and rapamycin did not induce these events. Adoptive transfer of CD4<sup>+</sup>CD25<sup>+</sup> T cells isolated from LNP-Col II-R-injected mice suggested that T<sub>regs</sub> induced by LNP-Col II-R injection were likely responsible for the therapeutic effects. Collectively, this study suggests nanoparticle-mediated immunomodulation in the joint as a simple and effective treatment for OA.
Medical subject headings
- Osteoarthritis
- Nanoparticles